In view of the well-known androgen sensitivity of PCa, patients with metastatic or recurrent disease, despite the treatment, are usually subjected to androgen deprivation therapy (ADT), consisting of luteinizing hormone releasing hormone (LHRH) agonists or LHRH antagonists [5]. This evidence concerns the gene GNRH1 and posterior cortical atrophy.